Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 11, 2016 - Issue 2
Submit an article Journal homepage
2,790
Views
4
CrossRef citations to date
0
Altmetric
Drug Profiles

IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status

Jens Sandahl ChristiansenPreviously Department of Clinical Medicine – The Department of Endocrinology and Diabetes, Aarhus University, Aarhus, Denmark
,
Philip HomeInstitute of Cellular Medicine – Diabetes, Newcastle University, Newcastle upon Tyne, United KingdomCorrespondence[email protected]
&
Ajay KumarDiabetes Care and Research Centre, Kankarbagh, Patna, India
Pages 103-111 | Received 31 Jul 2015, Accepted 20 Jan 2016, Published online: 26 Feb 2016

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Adri Kok, Hemant Makan, Gracjan Piotr Podgorski, Shaifali Joshi, Verushka Chetty, Lungisa Nojoko, Hajira Bacus, Naeem Moosa & Duma Khutsoane. (2023) Initiating or switching to IDegAsp in a real-world South African population with type 2 diabetes – a cohort analysis from the ARISE study. Journal of Endocrinology, Metabolism and Diabetes of South Africa 28:3, pages 92-99.
Read now

Articles from other publishers (3)

Tao Long, Jin-ting Lin, Min-hua Lin, Qian-long Wu, Jian-mei Lai, Sheng-zhen Li, Zi-chao Zhou, Ji-yuan Zeng, Jia-shuan Huang, Chun-ping Zeng & Yao-ming Lai. (2022) Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine Journal 69:8, pages 959-969.
Crossref
Shinje Moon, Hye-Soo Chung, Yoon-Jung Kim, Jae-Myung Yu, Woo-Ju Jeong, Jiwon Park & Chang-Myung Oh. (2021) Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis. Metabolites 11:9, pages 639.
Crossref
Tim Heise & Chantal Mathieu. (2017) Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes, Obesity and Metabolism 19:1, pages 3-12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.